Intact Versus Biointact Assays for Longitudinal Assessment of Parathyroid Hormone - The Longitudinal PTH Study
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Medical University of Vienna
- Enrollment
- 132
- Locations
- 1
- Primary Endpoint
- Longitudinal change in PTH levels measured in [pg/ml]
Study Overview
Brief Summary
The main study aim is to quantify the agreement between the analytical results provided by two third generation and two second generation Parathyroid hormone (PTH) assays. The primary comparison will be performed between the second-generation PTH assay"Intact PTH assay" from Siemens Healthcare Diagnostics Inc. and the third-generation PTH assay "biointact (1-84)" from Roche Diagnostics in terms of a Bland-Altman analysis. Several studies have evaluated the correlation between various PTH assays at a single time-point, but no previous study has tested the hypothesis that longitudinal changes in PTH levels, which are important for making treatment decisions, can be monitored by several PTH assays alike. To this aim, the key secondary objective is to analyze the longitudinal variance in PTH over the course of 1 year, using each of two assays of the second and third generations, respectively. Other secondary objectives include determining changes in serum phosphate, serum calcium, fibroblast growth factor 23 (FGF23), with respect to treatment decisions. For clinical applicability of the results to be obtained here, an important goal of the present study will be not to influence treatment decisions, which will remain independent of the study investigators, at the full responsibility of the hemodialysis physicians.
At every quarterly blood draw over the course of one year, the investigators will freeze the serum from 100 patients, and at the end of 4 quarters the investigators will analyze PTH-levels using the following assays: Intact Parathyroid Hormone (Advia Centaur, Siemens Healthcare), PTH-Intact (Cobas, Roche), PTH (1-84) - The agreement between the PTH assays will be analyzed at baseline, as well as at the subsequent quarterly evaluation time-points by Bland-Altman analysis and complemented by Passing-Bablok regression. The longitudinal changes in PTH will be displayed graphically and analyzed by estimating the within-patient variance across time, the between patient variance at each time-point as well as effects on the mean log-PTH level due to course of disease and therapeutic interventions from a linear mixed model.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •All patients who were undergoing uninterrupted hemodialysis or hemodiafiltration at the Chronic Hemodialysis Unit of the Division of Nephrology and Dialysis, Medical University of Vienna between November 1st, 2017 and December 31st,
- •Existence of residual blood samples from four successive quarterly routine controls
- •Age ≥ 18 years
- •The test result of the assay must not have any diagnostic value or therapeutic consequence for the patients included in this study.
Exclusion Criteria
- •Death during the observational period (all patients must have lived through the 1-year period and must have all 4 quarterly blood draws performed on them).
- •Age <18 years
Outcomes
Primary Outcomes
Longitudinal change in PTH levels measured in [pg/ml]
Time Frame: Timepoints of four consecutive quarterly routine controls per patient (month 1; month 4 ; month 8, month 12)
PTH levels as measured by the second and third generation assays
Secondary Outcomes
- Serum Calcium levels(Timepoints of four consecutive quarterly routine controls per patient (month 1; month 4 ; month 8, month 12))
- Longitudinal within-patient change of PTH levels in [pg/ml](Timepoints of four consecutive quarterly routine controls per patient (month 1; month 4 ; month 8, month 12))
- Serum Phosphate levels(Timepoints of four consecutive quarterly routine controls per patient (month 1; month 4 ; month 8, month 12))
- Fibroblast growth factor 23 (FGF23(Timepoints of four consecutive quarterly routine controls per patient (month 1; month 4 ; month 8, month 12))
Investigators
Assoc. Prof. Dr. Manfred Hecking, MD PhD
Ass.Professor Dr.
Medical University of Vienna